[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657965":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":40,"armGroups":41,"interventions":35,"overallOfficials":51,"centralContacts":55,"locations":65,"responsibleParty":83,"collaborators":35,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":35,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":35,"enrollmentInfo":94,"targetDuration":35,"studyType":97,"phases":35,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":109,"whyStopped":35,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":35},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Number of Participants With Recurrent Stroke","Recurrent stroke is defined as a new acute neurological deficit consistent with ischemic or hemorrhagic stroke occurring after enrollment and confirmed by clinical evaluation and brain imaging. Events will be assessed during follow-up visits at 30, 90, 180, and 360 days.","30 days, 90 days, 180 days, and 360 days after enrollment",{"measure":14,"description":15,"timeFrame":12},"Number of Participants With Symptomatic Intracranial Hemorrhage","Symptomatic intracranial hemorrhage is defined as a newly detected intracranial hemorrhage on brain imaging that is associated with neurological deterioration or other clinically relevant symptoms. Events will be assessed during follow-up visits at 30, 90, 180, and 360 days.",{"measure":17,"description":18,"timeFrame":12},"Number of Participants With Major Extracranial Bleeding","Major extracranial bleeding includes clinically significant bleeding outside the cranial cavity that results in death, occurs in a critical organ or site, requires blood transfusion, or causes a clinically significant decrease in hemoglobin. Events will be assessed during follow-up visits at 30, 90, 180, and 360 days.",[20,23,26,29,32],{"measure":21,"description":22,"timeFrame":12},"Number of Participants With Systemic Arterial Embolism","Systemic arterial embolism is defined as an acute arterial occlusion outside the central nervous system that is confirmed by clinical evaluation, imaging, surgery, or pathological examination.",{"measure":24,"description":25,"timeFrame":12},"Number of Participants With Venous Thromboembolism","Venous thromboembolism includes deep vein thrombosis and pulmonary embolism confirmed by an appropriate diagnostic imaging examination.",{"measure":27,"description":28,"timeFrame":12},"Number of Participants With Myocardial Infarction","Myocardial infarction will be identified on the basis of clinical symptoms, cardiac biomarkers, electrocardiographic findings, and cardiac imaging, as documented in the medical record.",{"measure":30,"description":31,"timeFrame":12},"Number of Participants Who Die From Any Cause","All-cause mortality is defined as death from any cause occurring during the follow-up period.",{"measure":33,"description":34,"timeFrame":12},"Functional Outcome Measured by the Modified Rankin Scale","Functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability or death. A score of 0 indicates no symptoms, and a score of 6 indicates death.",null,{"allocation":35,"interventionModel":35,"interventionModelDescription":35,"primaryPurpose":35,"observationalModel":37,"timePerspective":38,"maskingInfo":35},"COHORT","PROSPECTIVE","The goal of this prospective observational study is to learn about the effectiveness and safety of different antithrombotic treatments in adults with a history of cancer and acute ischemic stroke. The main questions it aims to answer are:\n\n* Are there differences in the risk of recurrent stroke among patients receiving antiplatelet therapy, anticoagulant therapy, or combined therapy?\n* Are there differences among the treatment groups in the risk of symptomatic intracranial hemorrhage and major extracranial bleeding?\n* Are there differences among the treatment groups in the occurrence of systemic arterial embolism, venous thromboembolism, acute myocardial infarction, disability, and death?\n* Which clinical characteristics, stroke mechanisms, neuroimaging findings, cancer-related factors, and laboratory measurements are associated with treatment selection and clinical outcomes?\n\nParticipants will:\n\n* Be enrolled within 7 days after the onset of acute ischemic stroke or the last known well time.\n* Receive antiplatelet therapy, anticoagulant therapy, or combined therapy as selected by their treating physicians during routine clinical care.\n* Provide demographic, clinical, imaging, cancer-related, treatment-related, and laboratory information.\n* Provide blood samples for coagulation, platelet, inflammatory, hematologic, biochemical, and other planned assessments.\n* Complete follow-up assessments approximately 30, 90, 180, and 360 days after the index stroke.\n\nResearchers will compare the effectiveness and safety outcomes of patients receiving different antithrombotic treatments. The primary effectiveness outcome will be recurrent stroke. The primary safety outcomes will be symptomatic intracranial hemorrhage and major extracranial bleeding. Other outcomes will include systemic arterial embolism, venous thromboembolism, acute myocardial infarction, functional status measured using the modified Rankin Scale, and all-cause mortality.\n\nPatients with either active or inactive cancer may be included. Cancer type, activity, stage, metastatic status, time since diagnosis, and previous or ongoing anticancer treatment will be recorded. Treatment will not be assigned or modified by the study protocol.","The study population will consist of consecutive adult patients admitted to Xuanwu Hospital and Characteristic Medical Center of Rocket Army with acute ischemic stroke and a history of a malignant tumor. A history of cancer includes both active and inactive cancer. Information on cancer type, stage, metastatic status, time since diagnosis, disease activity, and anticancer treatment will be collected. Antiplatelet, anticoagulant, or combined antithrombotic therapy will be prescribed by the treating physicians according to routine clinical practice and will not be assigned by the study protocol. Participants will be followed to evaluate recurrent stroke, bleeding events, other thromboembolic events, functional outcomes, and mortality.",[42,45,48],{"label":43,"type":35,"description":44,"interventionNames":35},"Antiplatelet Therapy Group","Patients with acute ischemic stroke and a history of cancer who receive antiplatelet therapy for secondary stroke prevention. The treatment regimen is determined by the treating physician as part of routine clinical care and is not assigned by the study protocol.",{"label":46,"type":35,"description":47,"interventionNames":35},"Anticoagulant Therapy Group","Patients with acute ischemic stroke and a history of cancer who receive anticoagulant therapy for secondary stroke prevention. The treatment regimen is determined by the treating physician as part of routine clinical care and is not assigned by the study protocol.",{"label":49,"type":35,"description":50,"interventionNames":35},"Combined Antiplatelet and Anticoagulant Therapy Group","Patients with acute ischemic stroke and a history of cancer who receive combined antiplatelet and anticoagulant therapy for secondary stroke prevention. The treatment regimen is determined by the treating physician as part of routine clinical care and is not assigned by the study protocol.",[52],{"name":53,"affiliation":5,"role":54},"Hongyan Li, MD, PhD","PRINCIPAL_INVESTIGATOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":35,"email":60},"Hongyan Li","CONTACT","+86-18600346925","hongyanli@xwhosp.org",{"name":62,"role":58,"phone":63,"phoneExt":35,"email":64},"Chen Zhang","+86-18511551659","cherinezhang@163.com",[66],{"facility":67,"status":35,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Xuanwu Hospital, Capital Medical University","Beijing","Beijing Municipality","100000","China","CN",{"type":74,"coordinates":75},"Point",[76,77],116.39723,39.9075,{"lat":77,"lon":76},[80,81],{"name":53,"role":58,"phone":59,"phoneExt":35,"email":60},{"name":82,"role":58,"phone":63,"phoneExt":35,"email":64},"Chen Zhang, MD, PhD",{"type":84,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100657965","a-prospective-study-to-observe-clinical-outcomes-in-patients-receiving-antiplatelet-or-anticoagulant-therapy-for-cancer-associated-acute-ischemic-stroke-100657965",false,"NCT07845903","A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke","A Prospective Observational Cohort Study Evaluating the Effectiveness and Safety of Antiplatelet and Anticoagulant Therapies in Patients With Active Cancer and Acute Ischemic Stroke","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosis of acute ischemic stroke confirmed by clinical evaluation and brain imaging.\n* Enrollment within 7 days after symptom onset or the time the participant was last known to be well.\n* History of a malignant tumor, regardless of whether the cancer is currently active or inactive.\n* Written informed consent provided by the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* Hematologic malignancy.\n* Primary intracerebral hemorrhage, subarachnoid hemorrhage, or another non-ischemic type of stroke.\n* Transient ischemic attack without evidence of acute ischemic stroke.\n* Pregnancy or breastfeeding.\n* Known severe congenital coagulation disorder.\n* Collection of research blood samples would delay intravenous thrombolysis, mechanical thrombectomy, or other necessary treatment.\n* Blood samples that do not meet the prespecified collection requirements or show severe hemolysis.\n* Inability to obtain reliable medical history or outcome information from the participant, medical records, or an authorized representative.","ALL","18 Years",{"count":95,"type":96},60,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the effectiveness and safety of antiplatelet and anticoagulant treatments in people with a history of cancer who have acute ischemic stroke. The main questions it aims to answer are:\n\n* Are there differences in the risk of another stroke between people receiving antiplatelet treatment and those receiving anticoagulant treatment?\n* Are there differences in the risk of bleeding between the treatment groups?\n* Which clinical characteristics, imaging findings, cancer-related factors, and blood test results are associated with treatment outcomes?\n\nParticipants will:\n\n* Receive antiplatelet treatment, anticoagulant treatment, or a combination of both, as selected by their treating physicians during routine clinical care.\n* Provide clinical information and blood samples for the study.\n* Complete follow-up assessments approximately 30, 90, 180, and 360 days after the stroke.\n\nResearchers will compare recurrent stroke, bleeding, other blood clot-related events, functional recovery, and survival among participants receiving different antithrombotic treatments. The study will not assign or change participants' treatments.",[100,101],"Acute Ischemic Stroke","Cancer",[103,104,105,106,107,108],"History of Cancer","Antiplatelet Therapy","Anticoagulant Therapy","Antithrombotic Therapy","Secondary Stroke Prevention","Recurrent Stroke","NOT_YET_RECRUITING","2026-09-28",{"date":112,"type":113},"2026-09-29","ACTUAL",{"date":115,"type":96},"2026-09",{"date":117,"type":96},"2029-08",{"name":5,"class":6},1]